BioSpace News Archive

Pharm Country

PAVmed Announces Closing of Firm Commitment Common Stock Offering

PAVmed announced underwritten public offering of 2,415,278 shares of its common stock at a public offering price of $1.80 per share.

January 23, 2018
·
4 min read
Biotech Beach

Aerie Pharmaceuticals Announces Public Offering of Common Stock

Aerie today announced that it has commenced a registered underwritten public offering of $75 million of shares of its common stock.

January 23, 2018
·
3 min read
Genetown

Ultivue Inc. Announces Completion of its Series B Financing

Ultivue Inc. announced today that it has closed a $20 million Series B funding round led by existing investor ARCH Venture Partners.

January 23, 2018
·
2 min read
Business

MIVI Neuroscience Selects Bob Colloton to Lead Worldwide Commercialization Of Innovative Treatment Solution for Ischemic Stroke

Bob brings 27 years of proven experience in medical device sales and market development and branding expertise, with a deep understanding of the neurovascular market in particular.

January 23, 2018
·
2 min read
Policy

FDA Accepts Investigational NDA and Grants Fast Track Status for Sobi’s SOBI003 for the Treatment of MPS IIIA

The clinical study with SOBI003 is expected to start during 2018.

January 23, 2018
·
3 min read
Business

Atomo Diagnostics and Access Bio Partner to Expand Access to Best-in-Class HIV Rapid Testing in Global Markets

Atomo Diagnostics and Access Bio Inc. today announce a strategic partnership to leverage the respective strengths of both innovative rapid diagnostic test (RDT) companies to expand point of care HIV testing in global markets.

January 23, 2018
·
4 min read
Business

Marken Opens New Location In Stuttgart, Germany

Marken today announced it will open a third branch in Germany in the first quarter of 2018 to meet new demands in the region.

January 23, 2018
·
2 min read
Drug Development

BioLineRx Reports Data at ASCO-SITC Conference Showing Complete Tumor Regression by AGI-134 in Pre-Clinical Studies

BioLineRx announced today that AGI-134, an immunotherapy compound in development for the treatment of multiple solid tumors, demonstrated successful results in two pre-clinical melanoma studies.

January 23, 2018
·
6 min read
Drug Development

Evofem Biosciences Announces First Patient Enrolled in Phase Ib/III STI Trial of Amphora and Expects Phase III Contraceptive Clinical Trial Data First Quarter 2019

Evofem Biosciences today announced enrollment of the first patient in a Phase 2b/3 clinical trial evaluating Amphora and its ability to prevent urogenital chlamydia and gonorrhea in women.

January 23, 2018
·
5 min read
Drug Development

ProMIS Neurosciences Lead Product Candidate for Alzheimer’s Disease Shows Potential for Improved Therapeutic Potency Versus Other Amyloid Beta-Directed Antibodies

ProMis Neurosciences today announced further results of its previously announced and ongoing preclinical program for Alzheimer’s disease.

January 23, 2018
·
5 min read